153results about "Microbiology" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

Provided are methods for identifying and treating patients with cancer, where the cancer expresses CEACAM5. The methods include measuring circulating CEA to identify patients likely to benefit from treatment with an agent specific for CEACAM5. Such patients can have high circulating CEA and only low or medium expression of CEACAM5 on tumor cells as measured by immunohistochemistry (IHC). The agent specific for CEACAM5 can be tusamitamab ravtansine. Such agent can be used in combination with one or more additional agents to treat the cancer. In certain embodiments the cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Disclosed herein are methods and compositions to predict a response of a subject to a nutrient modulation therapy. Restricting the uptake of at least one amino acid by cancer cells can be used to treat or delay cancer. In some embodiments, the nutrition modulation therapy is a dietary product that is substantially devoid of at least one amino acid.

Method for single molecule localization microscopy (SMLM) based on conventional fluorescent binder probes, including primary or secondary antibodies, that are applied in a gradual stepwise fashion to a fixed biological sample. In each step of the process, a low dose of the probe is applied in solution to the fixed biological sample to sparsely label target epitopes followed by sample washing to remove the free probe. The remaining bound fluorescent probes that are sparsely distributed over the sample are then imaged until they are photobleached. The high light collection efficiency from each probe in this approach (limited only by photobleaching) enables few Ångstrom lateral resolution and few nm axial resolution. Photobleaching of the probes at the end of each step generates a clean slate for application of the next step in the process, as well as the possibility for applying one or more probes in a consecutive fashion to the same sample for serial SMLM.

The invention discloses a skeletal muscle repair method and system based on muscle satellite cell regulation and control. The method comprises the following steps: performing proliferation and differentiation correlation analysis on satellite cell steady state data and aerobic exercise intensity data to establish a proliferation regulation and control map; determining a collaborative repair time window according to the atlas, extracting difference response deviation correction parameters to form an activity correction factor, and performing repair intensity correction on the collaborative repair time window to generate a self-adaptive repair window; carrying out exercise prescription adaptation on the self-adaptive repair window, identifying a satellite cell activation regulation and control channel, obtaining activation delay time through activation efficiency mapping, and delimiting a response level according to the activation delay time to generate layered repair configuration; activation delay evaluation is conducted on layered repair configuration to determine a preferred activation mode, dynamic activation characteristics are extracted based on optimal activation time window data to form an intervention execution sequence, a skeletal muscle repair execution instruction is output in combination with an exercise prescription parameter table, and dynamic collaborative adaptation of satellite cell repair state monitoring and training scheme parameters is achieved.

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell–inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

A method to produce a rapid immunohistochemical detection of an antigen from a biological sample is provided. Preferably, the method may be used for rapid immunohistochemical staining of a biological sample that allows completion of the staining process in less than ten minutes, such as during a cancer removal procedure. Preferably, the method may include the steps of: depositing a section of the biological sample on a slide; permeabilizing the section of the biological sample; incubating the section of the biological sample with a secondary antibody having a detectable label; removing unbound secondary antibody from the section of the biological sample; mounting the section of the biological sample; and detecting secondary antibody bound to the section of the biological sample.

Here provided an antibody YWHG-1 against HLA-G molecule and use thereof. The antibody is produced by the hybridoma deposited under CCTCC NO: 202120, and is prepared by an immunogen with amino acids which are common to seven known HLA-G isoforms (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) which is located at positions 72-91 (QTDRMNLQTLRGYYNQSEAS) in the heavy chain α1 domain of the HLA-G molecule. The present invention provides nucleotides encoding the antibody YWHG-1 and encoded amino acid sequences thereof. The antibody YWHG-1 can be used for immunohistochemistry, immunoblotting, flow cytometry and other assays for HLA-G isoforms.

The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg / mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.

The present application describes a method for reducing background fluorescence in single molecule fluorescence in situ hybridization applications, wherein first Sudan Black B is applied to formalin-fixed, paraffin-embedded tissue sections and thereafter the single molecule fluorescence in situ hybridization application is carried out. Furthermore, there is described the use of Sudan Black B for reducing background fluorescence in single molecule fluorescence in situ hybridization applications.

The invention discloses a method for improving the dispersion degree of a sample spot edge of a liquid quality control product, which comprises the following steps: pretreating an EP tube loaded with the liquid quality control product: soaking the EP tube in a surfactant solution, directly draining water, and completely drying in a drying oven; the surfactant solution is one of a Tween-20 solution with the volume concentration of 1%-12%, a Tween-80 solution with the volume concentration of 2%-15% and a Triton-100 solution with the volume concentration of 5%-20%. The pre-treated EP tube is used for loading the liquid quality control product, so that the'coffee ring 'phenomenon can be eliminated in the subsequent sample application process of the liquid quality control product, the quality control product is dispersed more uniformly, the diameter of a sample application spot is not obviously influenced under treatment of different concentrations, and the treated liquid quality control product has the advantages of uniform sample application spot diameter and high quality. The subsequent immunohistochemical staining performance of the liquid quality control product is not influenced.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The present disclosure provides methods and systems for predicting a subject's diagnostic status with respect to a disease or disorder. The method may comprise staining a tooth, hair, or nail sample of the subject to produce a stained tooth sample, analyzing a fluorescence intensity spatially across the stained tooth, hair, or nail sample, and predicting a subject's diagnostic status with respect to a disease or disorder based at least in part on the analysis of the fluorescence intensity.

The present invention provides a method of treating a patient diagnosed with Myxoid / Round cell liposarcoma with an anti-GPC3 therapeutic agent. The present invention also relates to quantification of GPC3 expression in tissue samples of patients diagnosed with Myxoid / Round cell liposarcoma by an immunostaining assay and identification of GPC3 expression levels that correlate with selection of patients for administering the anti-GPC3 therapeutic agent.

The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

A method for identifying, prior to treatment, cancer patients who respond to anti-CLEVER-1 therapy, which includes administration of an agent capable of binding to common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) in a patient. In this method, the presence of PD-L1-expressing cells and CLEVER-1-expressing cells is detected in a tumor sample obtained from a cancer patient by immunohistochemical staining with a PD-L1-specific antibody and a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and the ratio of PD-L1-expressing cells from the total amount of viable cells present in the stained sample and the ratio of CLEVER-1-expressing cells within the tumor from the total amount of viable tumor cells present in the stained sample are calculated. A tumor sample with a low ratio of PD-L1-expressing cells or no PD-L1-expressing cells and a significant proportion of CLEVER-1-expressing cells within the tumor indicates that the cancer patient is responsive to anti-CLEVER-1 therapy.

The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.

The present disclosure provides an antibody for predicting breast cancer prognosis and a nucleic acid encoding sequence thereof, and uses of the same. The antibody for predicting breast cancer prognosis of the present disclosure achieves the effect of predicting breast cancer prognosis through various efficacy experiments.

Provided herein are methods of treating cancer in a subject in need thereof. The method includes obtaining a tumor sample from the subject and detecting an expression level(s) of one or more genes in a tumor sample. In certain embodiments, the genes comprise MMP13, XAF1, IGFBP3, MX2, IFIT1, ISG15, OAS3, CXCL10, SERPINE1, CXCL11, and CXCL3. A change in the expression level of the one or more genes as compared to a control level indicates Mic60-depleted cancer. The method further includes treating the subject for Mic60-depleted cancer.

The present invention relates to methods and systems for detecting one or more analytes in a sample and / or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and / or absence of analyte is within ± 50% of the Forster distance.

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

The invention discloses a biological combined marker for predicting radiotherapy sensitivity of esophageal squamous cell carcinoma and application of the biological combined marker, and belongs to the technical field of biological medicine, and the biological combined marker is composed of EZH2, ENOSF1 and PGM5. According to the invention, EZH2 related to ESCC radiotherapy sensitivity and downstream target genes ENOSF1 and PGM5 thereof are screened out through a bioinformatics technology. In ESCC sensitive to radiotherapy, the expression level of EZH2 is relatively low, and the expression levels of ENOSF1 and PGM5 are relatively high. A tissue immunohistochemical method further proves that the expression levels of the EZH2 and the downstream target genes ENOSF1 and PGM5 thereof are related to the radiotherapy sensitivity of the ESCC patient, and the radiotherapy effect can be accurately predicted. Based on the three genes, a combined biomarker model for predicting the radiotherapy sensitivity of the ESCC patient is established, and the combined biomarker model has important clinical significance in predicting the radiotherapy sensitivity of the esophageal squamous cell carcinoma and improving the radiotherapy treatment effect of the patient.

Scoring functions for predicting response of a dMMR and / or MSI-H colorectal tumor to a PD-1 axis-directed therapy are disclosed, as well as methods and systems for evaluating tissue samples for the presence of feature metrics useful in computing such scoring functions. The scoring functions integrate one or more spatial relationships between cell types into a numerical indication of the likelihood that the tumor will respond to the PD-1 axis-directed therapy. Based on the output of the scoring function, a subject may then be selected to receive a PD-1 axis-directed therapy (if the scoring function indicates a sufficient likelihood of positive response) or an alternative therapy (if the scoring function indicates an insufficient likelihood of positive response).

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.